Quick Answer
Tevogen Bio Holdings Inc. reported R&D Expense of $11.11 million for fiscal year 2025.
Tevogen Bio Holdings Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.11M | -64.2% |
| 2024 | $31.03M | +604.7% |
| 2023 | $4.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.11M | -4.6% | +15.2% |
| June 30, 2025 | $2.70M | -34.5% | -15.5% |
| March 31, 2025 | $3.20M | -84.6% | -2.0% |
| September 30, 2024 | $3.26M | +192.0% | -20.9% |
| June 30, 2024 | $4.12M | +299.9% | -80.2% |
| March 31, 2024 | $20.81M | +1444.8% | +1763.3% |
| September 30, 2023 | $1.12M | — | +8.3% |
| June 30, 2023 | $1.03M | — | -23.4% |
- Tevogen Bio Holdings Inc. showed a decrease of -64.2% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Tevogen Bio Holdings Inc.’s r&d expense has grown by 152.3% (from $4.40 million to $11.11 million).
- The most recent figure is from Tevogen Bio Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: